Early pharmaceutical treatment for<unk>  may include supplementing vitamin D and the use of cinacalcet. Cinacalcet acts to increase the sensitivity of the calcium sensing receptors to calcium leading to a reduction in parathyroid hormone release, however, its use has limited impact in those with<unk> . These treatments are more likely only transient therapies before parathyroidectomy is performed. Indications for surgery in<unk>  commonly involve the development of chronic, severe conditions including osteopenia, persistent severe hypercalcemia, bone pain and pathologic fracture. Other indications include development of conditions such calciphylaxis. Surgical options for<unk>  include subtotal parathyroidectomy (three and one half of total tissue) and total parathyroidectomy with autotransplatation of resected tissue. Outcomes from surgery are generally favourable and a return to normalised blood calcium levels and parathyroid function is seen.
Tertiary hyperparathyroidism
Primary hyperparathyroidism
Secondary hyperparathyroidism
Familial hypocalciuric hypercalcemia
Normophosphatemic familial tumoral calcinosis
Parathyroid adenoma
Pseudohypoparathyroidism
Pseudopseudohypoparathyroidism